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Management of early chronic kidney disease in indigenous pop-
ulations and ethnic minorities. The rate of treated end-stage
renal disease (ESRD) continues to increase globally. The dis-
proportionately high rate of ESRD among the many growing in-
digenous populations and racial/ethnic minorities in the United
States highlights the need to reassess present treatment strate-
gies to more appropriately identify and manage chronic kid-
ney disease in diverse communities. Similar projections have
been noted worldwide. This discrepancy between ESRD rates
among racial and ethnic minority groups, and treatment strate-
gies is due to several factors, many of which are modifiable.
These include the individual, the health care provider/system,
and limited participation in controlled clinical trials. Although
it is unfortunate that this disparity continues to exist, a thought-
ful and compassionate approach to addressing the role of di-
verse biobehavioral and sociocultural factors might be the key
to effective translation of emerging scientific advances into im-
proved clinical outcomes for all patients with chronic kidney
disease.
Resumen
Los grupos afro y mexicano americanos presentan una tasa
desproporcionadamente elevada de insuficiencia renal cro´nica,
en comparacio´n con individuos de raza blanca. Un mejor
conocimiento de los factores de riesgo tradicionales como de
los novedosos de la enfermedad renal cro´nica (ERC) en gru-
pos raciales y e´tnicos minoritarios, pudiera facilitar la aplicacio´n
de mejores estrategias de prevencio´n, deteccio´n y tratamiento
oportuno de ella. Los hallazgos en estas poblaciones de alto
riesgo se pudieran aplicar para mejorar los resultados en to-
dos los pacientes con ERC, no solo en los Estados Unidos,
sino a nivel global. Adema´s, sus implicaciones econo´micas y las
polı´ticas de salud implı´citas, son igualmente importantes para
asegurar una asignacio´n costo efectiva de los escasos recursos
econo´micos disponibles.
Epidemiologic data have demonstrated a rise in end-
stage renal disease (ESRD), particularly in indigenous
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populations worldwide and ethnic minorities in the
United States [1–4]. In the United States, African Ameri-
cans have the highest rates of ESRD (988 per million), fol-
lowed by indigenous Native Americans (696 per million),
Asians (395 per million), and whites (254 per million).
When stratified as Hispanic and non-Hispanic whites, the
incidence rates are 471 and 325 per million, respectively
[3]. The progressive rise in the US indigenous popula-
tion and ethnic minorities [5] increases the likelihood that
the overall rate of ESRD will increase even more rapidly
over the next several years. Similar projections have been
noted for the United Kingdom [1].
Diabetes mellitus (DM), followed by hypertension, re-
mains the leading cause of ESRD in the United States,
accounting for approximately 75% of new cases annu-
ally [3]. The increasing rate of DM globally [6] is now the
driving force behind the epidemic growth of CKD and
ESRD [3]. In the United States, the prevalence of mild-
to-moderate or early CKD (stages 1–3, glomerular filtra-
tion rate ≥30 mL/min/1.73 m2) is not disproportionately
increased among racial and ethnic minorities, compared
with whites [7], which suggests that other factors may
play an important role in the progression of early CKD
toward ESRD [8, 9]. These include, but are not limited
to, higher rates of CKD risk factors [10], lower rates of
control of comorbid diseases [11–13], differences in ac-
cess to quality care from the health care system [14, 15],
and differences in response to therapy [16–18].
Higher rates of many modifiable metabolic-related
disorders such as obesity, diabetes mellitus, and hyper-
tension, and/or lower rates of optimal control of these
disorders are more preponderant among indigenous pop-
ulations. This is especially true as indigenous populations
move from an environment with deficient or inconsistent
food sources to a Western diet and become increasingly
physically inactive in their new environment [19–21]. This
disparate lifestyle may be compounded by social institu-
tional structures that maintain factors such as poor hous-
ing, discrimination, limited economic advancement, low
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Fig. 1. Impact of colonization on indigenous health today with implications for chronic kidney disease (modified from [23]).
education and literacy rates, and limited access to effec-
tive health care (Fig. 1) [22, 23].
It is becoming increasingly apparent that changing en-
vironmental conditions and socioeconomic climate exerts
greater influence on the distribution of health and dis-
ease among human subpopulations. The human genome
project has advanced our understanding of the poten-
tial role of not only interracial but the even more sig-
nificant intraracial genetic variations in the distribution
of health and disease. The more serious concern lies in
the potential use of genetic data to foster exploitation
of indigenous populations in an attempt to understand
health disparities [24, 25]. Current advances in pharma-
cogenomics and evaluation of drug response by genetic
profiling promise to challenge our current view of age,
gender, race/ethnicity, and coexisting medical conditions
as predictors of health outcomes. Recognizing the in-
terdependence of basic science, clinical discovery, and
patient-oriented research [26] will allow a more complete
understanding of gene-gene, gene-environment, and ac-
tionable modifiers of gene expression. Such a unified ap-
proach would address current concerns about our present
strategies for translating emerging biomedical and clini-
cal research practices to improve clinical outcomes [27].
PREVENTION/EARLY INTERVENTION
The key to prevention is to reduce and/or eliminate
major risk factors that contribute to CKD. For most in-
digenous and ethnic communities, the major risk factor
is the rising incidence of type II DM. Education to im-
prove awareness of diabetes, as well as hypertension and
a family history of CKD, are important for the identi-
fication of individuals at increased risk [28]. Screening
should include not only the assessment of historical risk
factors but measurement of HbA1C, blood pressure, and
urinary protein excretion as well [29]. Obesity is an im-
portant risk factor for diabetes and reduction of this and
other risk factors noted above require lifestyle modifica-
tions and/or pharmacologic intervention. Strategies that
engage and educate high-risk communities will be more
effective if they seek and study input from the community
on all levels (eg, individual, provider, health system) of
barriers that exist and are potentially modifiable.
INDIGENOUS AND ETHNIC MINORITIES IN
CKD CLINICAL TRIALS
Despite emerging data supporting the role of
strict blood-pressure control and inhibition of the
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Table 1. Ethnic minority participation in kidney disease trials
Study Year Minorities in CKD trials
Lewis et al [36] 1993 In type I diabetics, ACEI reduced proteinuria, risk of doubling SCr, and risk of ESRD and death, but
not ESRD alone (N = 409; 4% AA).
REIN [37] 1997 In nondiabetics, ACEI reduced proteinuria, risk of doubling SCr, ESRD, and death. ESRD alone was
not reduced (N = 352; race not reported).
MDRD [38] 1997 Strict blood pressure control slowed the decline in GFR (N = 548; 9% black).
UKPDS [39] 1998 In type II diabetics, b-blocker = ACEI in improving clinical outcomes (N = 3867; 81% white, 10%
Indian/Asian, 8% black, 1% other).
Jafar et al [40] 2001 Meta-analysis 11 studies from 1992–1997 in nondiabetic CKD: ACEI > non ACEI (N = 2801; 6% black).
IRMA [41] 2001 ARB > non-ARB, non-ACEI in preventing diabetic nephropathy in hypertensive patients with type 2
diabetes and microalbuminuria (N = 590; 3% non-white).
IDNT [32] 2001 ARB > non-ARB, non-ACEI in reducing proteinuria and GFR progression in type II DM (N = 1715;
13% black, 5% Hispanic).
RENAAL [33] 2001 ARB > non-ARB, non-ACEI in reducing proteinuria and GFR progression in type II DM (N = 1513;
15% black, 18% Hispanic).
AASK [34] 2001–2 ACEI > b-blocker > amlodipine in reducing proteinuria and improving hard clinical outcomes in AA
with HTN-CKD (N = 1094; all black).
Abbreviations are: Scr, serum creatinine; ESRD, end-stage renal disease, ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD,
chronic kidney disease; AA, African American; GFR, glomerular filtration rate; HTN, hypertension; DM, diabetes mellitus.
renin-angiotensin-aldosterone system (RAAS) in delay-
ing or halting the progression of CKD, there continues to
be a progressive increase in the rate of ESRD. Many clin-
ical trials that demonstrated improved CKD and clinical
composite outcomes have unfortunately had low rates of
indigenous populations and ethnic minority enrollment
(Table 1), despite high rates of disease prevalence. This
is critical, because several other studies have suggested
that ethnic minorities exhibit suboptimal response to the
use of angiotensin-converting enzyme (ACE) inhibitors
in the treatment of hypertension [16] and left ventricular
dysfunction [17]. Also, the rate of ACE inhibitor-related
serious side effects is greater in ethnic minorities [30, 31].
Thus, the inclusion of indigenous and racial/ethnic mi-
norities in controlled clinical trials is crucial to assess effi-
cacy and safety profiles that may be influenced by factors
ranging from varying prevalence rates of gene polymor-
phisms to dietary and cultural practices.
Fortunately, greater numbers of racial and ethnic mi-
norities have been included in more recently completed
randomized CKD trials; therefore, these interventions
could be applicable to indigenous populations around the
world. Of the 1715 participants enrolled in a study from
Lewis et al, 13% were black and 5% Hispanic [32]. Like-
wise, among the 1513 total participants enrolled in a study
from Brenner et al, 15% were black and 18% Hispanic
[33]. However, Native Americans were not enrolled in
these studies.
Although these numbers are not sufficient for gener-
ating independent analyses, the higher rates of minority
participants in the latter two studies strongly suggest that
positive outcomes are extended to blacks and Hispanics
as well as whites. Globally, it will be important to include
adequate numbers of high-risk populations as additional
randomized CKD trials are undertaken.
The African American Study of Kidney Disease and
Hypertension documented that ACE inhibitors were su-
perior to beta blockers and dihydropyridine calcium-
channel blockers in reducing the onset of doubling of
serum creatinine, ESRD, or death in patients with hy-
pertensive renal disease, which supports the efficacy and
safety of ACE inhibitors in African Americans with hy-
pertension and CKD [34]. Indeed, it has been suggested
that all Pima Indians with type II diabetes should be
placed on RAAS inhibition therapy [35]. Thus, emerg-
ing data from recent prospective randomized trials sug-
gest that RAAS interruption is both safe and effective
for treating CKD in indigenous and ethnically diverse
populations.
CONCLUSION
Indigenous and racial/ethnic minorities continue to suf-
fer from disproportionately high rates of ESRD. Globally,
diabetes mellitus is reaching epidemic proportions and
is the fastest-growing etiologic cause for patients enter-
ing the ESRD program. In view of the unique sociocul-
tural components that impact rates and control of risk
factors that promote progression of CKD, it is critical
that health beliefs and practices, and health care deliv-
ery be taken into account to develop and implement ef-
fective prevention strategies and early interventions. For
example, the development of linguistically and culturally
sensitive/appropriate educational messages that target
high-risk communities is critical if outreach programs are
to be effective.
Treatment with state-of-the-art therapy from con-
trolled trials appears to be effective and safe for all
patients with CKD, and the inclusion of high-risk pop-
ulations in future randomized CKD studies will provide
ongoing evidence-based understanding of the most effec-
tive treatment for patients with CKD.
Hopefully, these actions will attenuate the progres-
sive rise in CKD and ESRD with their attendant costs,
individual/community burden, and rising health care
expenditures, and ultimately contribute to a global
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achievement of increased quality and years of healthy
life.
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